|
T73834 |
NS5A-IN-2
|
|
HCV Protease
|
|
NS5A-IN-2 (Compound 33) serves as a potent NS5A inhibitor exhibiting exceptional efficacy against HCV genotype 1b, enhanced activity against genotype 3a (GT 3a), and notable metabolic stability [1]. |
|
T73223 |
NS5A-IN-3
|
|
HCV Protease
|
|
NS5A-IN-3 (Compound 15) serves as a potent NS5A inhibitor, displaying exceptionally high efficacy against HCV genotype 1b, enhanced activity towards genotype 3a (GT 3a), and substantial metabolic stability. It also demon... |
|
T74403 |
NS5A-IN-1
|
|
|
|
NS5A-IN-1 is a proagent of the HCV NS5A inhibitor Pibrentasvir (ABT-530). |
|
T74495 |
NS5A-IN-4
|
|
|
|
NS5A-IN-4 (Compound 1.12) is a pan-genotypic, orally active inhibitor of the hepatitis C virus (HCV) NS5A, exhibiting IC50 values of 1.2, 2296, 4.6, 362, 10.3, and 693 pM against genotypes gT1b, gT1a, gT2a, gT3a, gT4a, a... |
|
T25268 |
Coblopasvir
|
|
Others
|
|
Coblopasvir is a pan-genotypic non-structural protein 5A (NS5A) inhibitor. It can be used to study chronic hepatitis C virus infection. |
|
T11541 |
HCV-IN-30
|
|
Others
,
HCV Protease
|
|
HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons). |
|
T25268L |
Coblopasvir dihydrochloride
|
Coblopasvir dihydrochloride(1312608-46-0 Free base) |
HCV Protease
|
|
Coblopasvir dihydrochloride can be used to study chronic HCV infection and is a pan-genotypic nonstructural protein 5A (NS5A) inhibitor. |
|
T9567 |
Samatasvir
|
ATOLIHZIXHZSBA-BTSKBWHGSA-N,IDX719 |
HCV Protease
|
|
Samatasvir (ATOLIHZIXHZSBA-BTSKBWHGSA-N) is a pan-genotypic inhibitor of the HCV non-structural protein 5A. |
|
T6229 |
Daclatasvir
|
Daklinza,EBP 883,BMS-790052 |
HCV Protease
|
|
Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3. |
|
T1786 |
Daclatasvir dihydrochloride
|
BMS-790052 dihydrochloride |
HCV Protease
|
|
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to ... |
|
T5127 |
ABT530
|
ABT 530,ABT-530,Pibrentasvir |
HCV Protease
|
|
ABT530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6. |
|
T6200 |
Ledipasvir
|
GS-5885 |
HCV Protease
,
SARS-CoV
|
|
|
|
T4544 |
Elbasvir
|
MK-8742 |
HCV Protease
|
|
Elbasvir (MK-8742) is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection. |
|
T68015 |
Ruzasvir
|
MK8408,MK-8408,MK 8408 |
HCV Protease
|
|
Ruzasvir (MK-8408) is a novel and potent pan-genotypic inhibitor of hepatitis C virus NS5A with antiviral activity. |
|
T4203 |
Ledipasvir (acetone)
|
Ledipasvir acetone,GS-5885 acetone |
HCV Protease
|
|
Ledipasvir (acetone) (GS-5885 acetone) is an HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection. |
|
T24480 |
MK-8325
|
MK 8325,MK8325 |
HCV Protease
|
|
MK-8325 is a potent and orally available HCV NS5A inhibitor with replicative activity against a wide range of genotypes.MK-8325 has demonstrated bioavailability in in vitro and in vivo assays and has a favorable overall ... |
|
T3334 |
Velpatasvir
|
GS-5816 |
HCV Protease
,
SARS-CoV
|
|
Velpatasvir (GS-5816), also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 d... |
|
T7158 |
Ombitasvir
|
ABT-267 |
HCV Protease
|
|
Ombitasvir (ABT-267) is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype ... |
|
T11548 |
HCV-IN-7
|
|
Others
|
|
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. |
|
T11548L |
HCV-IN-7 hydrochloride
|
|
Others
|
|
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. |
|
T38858 |
GSK2818713
|
|
|
|
GSK2818713 is a novel Hepatitis C NS5A replication complex inhibitor. |
|
T24475 |
MK-4882
|
MK 4882,MK4882 |
|
|
MK-4882 is an effective inhibitor of HCV NS5A. |
|
T70731 |
Odalasvir
|
|
|
|
Odalasvir is a novel NS5A inhibitor for the treatment of hepatitis C. |
|
T30262 |
AZD-7295
|
A 831,A-831,AZD7295,A831 |
|
|
AZD-7295 (A-689) is an NS5A inhibitor that may be used to treat HCV infection. |
|
T27461 |
GSK2336805
|
GSK 2336805,GSK-2336805,JNJ-56914845,GSK-805,GSK805 |
|
|
GSK-2336805 is a HCV NS5A inhibitor. GSK2336805 retained activity on chimeric replicons containing NS5A patient sequences from genotype 1 and patient and consensus sequences for genotypes 4 and 5 and part of genotype 6. |
|
T24476 |
MK-6169
|
MK6169 |
|
|
MK-6169 is an effective Pan-Genotype Hepatitis C Virus NS5A inhibitor. It also has Optimized Activity against Common Resistance-Associated Substitutions. |
|
T71964 |
Ravidasvir HCl
|
|
|
|
Ravidasvir, also known as PPI-668 and ASC16, is a second-generation, orally active, potent and selective HCV NS5A protein inhibitor. |
|
T37915 |
Monodes(N-carboxymethyl)valine Daclatasvir
|
|
|
|
Monodes(N-carboxymethyl)valine Daclatasvir, also known as Daclatasvir Impurity A, is the principal degradation product of Daclatasvir.Daclatasvir is a potent inhibitor of the HCV NS5A protein[1]. |
|
T74006 |
Daclatasvir Impurity B
|
|
|
|
Daclatasvir Impurity B, a noted impurity of the antiviral agent Daclatasvir, acts as a potent inhibitor of the HCV NS5A protein [1]. |
|
T11832 |
Ledipasvir D-tartrate
|
GS-5885 D-tartrate |
Others
|
|
|
|
T78669 |
(1R,4S)-Yimitasvir diphosphate
|
(1R,4S)-DAG-181 diphosphate,(1R,4S)-Emitasvir diphosphate |
|
|
Yimitasvir diphosphate, also known as Emitasvir, is an orally-administered inhibitor of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A). It is utilized in the study of chronic hepatitis C virus infections [1]... |
|
T74589 |
Yimitasvir
|
|
|
|
Yimitasvir (Emitasvir), an orally administered inhibitor targeting the hepatitis C virus's (HCV) nonstructural protein 5A (NS5A), shows potential for the exploration of chronic HCV infection treatments [1]. |
|
T76524 |
Hepatitis C Virus S5A/5B
|
|
|
|
Hepatitis C Virus S5A/5B, a synthetic peptide substrate, replicates the NS5A/5B junction of the nonstructural protein (NS), serving as the substrate for examining HCV NS3 protease activity [1]. |
|
T74588 |
Yimitasvir diphosphate
|
|
|
|
Yimitasvir (Emitasvir) diphosphate is an orally administered inhibitor of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A), utilized in the research of chronic hepatitis C virus infection [1]. |
|
T74007 |
Daclatasvir Impurity C
|
|
|
|
Daclatasvir Impurity C is an impurity found in Daclatasvir, a robust inhibitor of the HCV NS5A protein [1]. |
|
T71085 |
BMS-824
|
|
|
|
BMS-824 is a potent NS5A inhibitor. The 50% inhibition of HCV replicon replication for BMS-824 was approximately 5 nM, with a therapeutic index of >10,000. BMS-824 showed good specificity for HCV, as it was not active... |
|
T27125 |
DBPR-110
|
MB110,MB 110,MB-110 |
|
|
DBPR-110 is a nonstructural protein 5A (NS5A) inhibitor. DBPR-110 reduced the reporter expression of the HCV1b replicon with a EC(50) and a selective index value of 3.9 ± 0.9 pM and >12,800,000, respectively. DBPR-110 re... |
|
T75241 |
Ledipasvir hydrochloride
|
GS-5885 hydrochloride |
|
|
Ledipasvir hydrochloride (GS-5885) is a hepatitis C virus NS5A inhibitor, displaying potent activity with EC50 values of 34 pM for genotype 1a replicon and 4 pM for genotype 1b replicon. Additionally, it acts as a SARS-C... |
|
TP1468 |
HCV-IN-4
|
|
|
|
HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) ar... |
|
T63090 |
SMCypI C31
|
|
|
|
SMCypIC31 is a non-peptide cyclophilin inhibitor that effectively inhibits peptidyl-prolyl cis/trans isomerase (PPIase) (IC50: 0.1 μM). SMCypI C31 has a pan-genotypic effect against HCV, with an EC50 range of 1.20-7.76 μ... |
